Stay updated on T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page.

Latest updates to the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange Detected- Replaced the older company/address block with a simplified company name addition and updated revision to v3.2.0. - Removed the older Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo and updated to Daiichi Sankyo with revision v3.2.0.SummaryDifference0.1%
- Check19 days agoChange DetectedUpdate to branding and version: the full address block is removed and the name is simplified to Daiichi Sankyo, with the revision updated from v3.0.2 to v3.1.0.SummaryDifference0.1%
- Check33 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; no substantive core-content changes were detected.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional drug information for Trastuzumab Deruxtecan, Capecitabine, and Paclitaxel. Notably, the total number of study locations has increased from 294 to 293, and several specific locations have been added or modified.SummaryDifference13%
- Check62 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
Stay in the know with updates to T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page.